98 related articles for article (PubMed ID: 22234468)
1. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice.
Nam DH; Lee MH; Kim JE; Song HK; Kang YS; Lee JE; Kim HW; Cha JJ; Hyun YY; Kim SH; Han SY; Han KH; Han JY; Cha DR
Endocrinology; 2012 Mar; 153(3):1387-96. PubMed ID: 22234468
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes.
Tedesco L; Valerio A; Cervino C; Cardile A; Pagano C; Vettor R; Pasquali R; Carruba MO; Marsicano G; Lutz B; Pagotto U; Nisoli E
Diabetes; 2008 Aug; 57(8):2028-36. PubMed ID: 18477809
[TBL] [Abstract][Full Text] [Related]
3. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
Tam J; Vemuri VK; Liu J; Bátkai S; Mukhopadhyay B; Godlewski G; Osei-Hyiaman D; Ohnuma S; Ambudkar SV; Pickel J; Makriyannis A; Kunos G
J Clin Invest; 2010 Aug; 120(8):2953-66. PubMed ID: 20664173
[TBL] [Abstract][Full Text] [Related]
4. Mulberry leaf extract and neochlorogenic acid ameliorate glucolipotoxicity-induced diabetic nephropathy in high-fat diet-fed db/db mice.
Hung TW; Yang MY; Yu MH; Tsai IN; Tsai YC; Chan KC; Wang CJ
Food Funct; 2023 Oct; 14(19):8975-8986. PubMed ID: 37732507
[TBL] [Abstract][Full Text] [Related]
5. Galantamine improves glycemic control and diabetic nephropathy in Lepr
Meng Q; Ma J; Suo L; Pruekprasert N; Chakrapani P; Cooney RN
Sci Rep; 2023 Sep; 13(1):15544. PubMed ID: 37731032
[TBL] [Abstract][Full Text] [Related]
6. Quercetin improves lipid metabolism via SCAP-SREBP2-LDLr signaling pathway in early stage diabetic nephropathy.
Jiang X; Yu J; Wang X; Ge J; Li N
Diabetes Metab Syndr Obes; 2019; 12():827-839. PubMed ID: 31239739
[No Abstract] [Full Text] [Related]
7. Effects of brown alga, Ecklonia cava on glucose and lipid metabolism in C57BL/KsJ-db/db mice, a model of type 2 diabetes mellitus.
Lee SH; Min KH; Han JS; Lee DH; Park DB; Jung WK; Park PJ; Jeon BT; Kim SK; Jeon YJ
Food Chem Toxicol; 2012 Mar; 50(3-4):575-82. PubMed ID: 22227338
[TBL] [Abstract][Full Text] [Related]
8. SMPDL3b modulates insulin receptor signaling in diabetic kidney disease.
Mitrofanova A; Mallela SK; Ducasa GM; Yoo TH; Rosenfeld-Gur E; Zelnik ID; Molina J; Varona Santos J; Ge M; Sloan A; Kim JJ; Pedigo C; Bryn J; Volosenco I; Faul C; Zeidan YH; Garcia Hernandez C; Mendez AJ; Leibiger I; Burke GW; Futerman AH; Barisoni L; Ishimoto Y; Inagi R; Merscher S; Fornoni A
Nat Commun; 2019 Jun; 10(1):2692. PubMed ID: 31217420
[TBL] [Abstract][Full Text] [Related]
9. Resting phase-administration of lemborexant ameliorates sleep and glucose tolerance in type 2 diabetic mice.
Tsuneki H; Sugiyama M; Sato K; Ito H; Nagai S; Kon K; Wada T; Kobayashi N; Okada T; Toyooka N; Kawasaki M; Ito T; Otsubo R; Okuzaki D; Yasui T; Sasaoka T
Eur J Pharmacol; 2023 Dec; 961():176190. PubMed ID: 37952563
[TBL] [Abstract][Full Text] [Related]
10. Anti-diabetic effect of
Xie Y; Xiao M; Li D; Liu H; Yun F; Wei Y; Sang S; Du G
Exp Ther Med; 2017 Apr; 13(4):1321-1328. PubMed ID: 28413472
[TBL] [Abstract][Full Text] [Related]
11. SIRT6's function in controlling the metabolism of lipids and glucose in diabetic nephropathy.
Wang Y; Liu T; Cai Y; Liu W; Guo J
Front Endocrinol (Lausanne); 2023; 14():1244705. PubMed ID: 37876546
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms underlying restoration of hepatic insulin sensitivity with CB1 antagonism in the obese dog model.
Kim SP
Adipocyte; 2013 Jan; 2(1):47-49. PubMed ID: 23700552
[TBL] [Abstract][Full Text] [Related]
13. Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II.
Guo X; Zhou G; Guo M; Cheung AK; Huang Y; Beddhu S
Physiol Rep; 2014 Feb; 2(2):e00230. PubMed ID: 24744899
[TBL] [Abstract][Full Text] [Related]
14. Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity.
Boon MR; Kooijman S; van Dam AD; Pelgrom LR; Berbée JF; Visseren CA; van Aggele RC; van den Hoek AM; Sips HC; Lombès M; Havekes LM; Tamsma JT; Guigas B; Meijer OC; Jukema JW; Rensen PC
FASEB J; 2014 Dec; 28(12):5361-75. PubMed ID: 25154875
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.
Kim HW; Lee JE; Cha JJ; Hyun YY; Kim JE; Lee MH; Song HK; Nam DH; Han JY; Han SY; Han KH; Kang YS; Cha DR
Endocrinology; 2013 Sep; 154(9):3366-76. PubMed ID: 23825123
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid-1 receptor regulates mitochondrial dynamics and function in renal proximal tubular cells.
Drori A; Permyakova A; Hadar R; Udi S; Nemirovski A; Tam J
Diabetes Obes Metab; 2019 Jan; 21(1):146-159. PubMed ID: 30091204
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy.
Jourdan T; Park JK; Varga ZV; Pálóczi J; Coffey NJ; Rosenberg AZ; Godlewski G; Cinar R; Mackie K; Pacher P; Kunos G
Diabetes Obes Metab; 2018 Mar; 20(3):698-708. PubMed ID: 29106063
[TBL] [Abstract][Full Text] [Related]
18. The intervention of cannabinoid receptor in chronic and acute kidney disease animal models: a systematic review and meta-analysis.
Zhao Z; Yan Q; Xie J; Liu Z; Liu F; Liu Y; Zhou S; Pan S; Liu D; Duan J; Liu Z
Diabetol Metab Syndr; 2024 Feb; 16(1):45. PubMed ID: 38360685
[TBL] [Abstract][Full Text] [Related]
19. The synthetic cannabinoids menace: a review of health risks and toxicity.
Alzu'bi A; Almahasneh F; Khasawneh R; Abu-El-Rub E; Baker WB; Al-Zoubi RM
Eur J Med Res; 2024 Jan; 29(1):49. PubMed ID: 38216984
[TBL] [Abstract][Full Text] [Related]
20. Renal Endocannabinoid Dysregulation in Obesity-Induced Chronic Kidney Disease in Humans.
Permyakova A; Rothner A; Knapp S; Nemirovski A; Ben-Zvi D; Tam J
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
